Abstract
clobazam, felbamate, lamotrigine, rufinamide, topiramate, divalproex sodium, and more recently cannabidiol. 3, 4 The characteristic EEG pattern in patients with LGS is diffuse background slowing, generalized 1.5-to 2.5-Hz spike-andwave discharges, and generalized paroxysmal fast activity. 4 Intellectual disability is common and may be progressive.
Late-onset LGS has been described in a few isolated reports, including in 2 patients with 15q duplication. 5, 6 The clinical features and outcome have not been well characterized previously. A previous study identified 3 patients who were considered to have late-onset LGS and demonstrated reduced fractional anisotropy in the white matter of the brainstem, suggesting that brainstem dysfunction may play a role. 3 Our aim was to characterize the clinical features, laboratory and EEG findings, and outcome in a cohort of patients with late-onset LGS.
Methods
We retrospectively identified patients with epilepsy consistent with late-onset LGS from medical records of all patients with seizure disorders who underwent treatment at Mayo Clinic in Rochester, Minnesota, from January 1, 2000, to March 1, 2017 . Patients aged 18 years or older were identified using the following search terms: Lennox-Gastaut, LennoxGastaut variant, intractable generalized idiopathic epilepsy, and drug-resistant generalized epilepsy. A total of 453 consecutive patients were identified. From this group, the following inclusion criteria were applied: (1) multiple seizure types that invariably included tonic and atonic seizures; (2) undergone a comprehensive epilepsy evaluation at our institution to include long-term video-EEG recordings in the inpatient epilepsy monitoring unit; (3) the electroclinical correlation supported the syndromic diagnosis of LGS; and (4) age at clinical onset of LGS at ≥10 years. Data extracted for purposes of this study included seizure types, etiologic factors, comorbidities, EEG results, neuroimaging findings, therapeutic interventions, and psychosocial outcome.
Standard protocol approvals, registrations, and patient consents An institutional review board approved the use of humans for this study.
Data availability
Anonymized data will be shared by request to any qualified investigator.
Results

Demographics and clinic features
Ten patients (8 females) were identified (table). The mean age at onset of seizures consistent with LGS was 16.5 years (range, 10-32 years), and the mean age at seizure onset was 12.2 years (range, 5-19 years). Two patients had seizure onset before age 10 years but did not have the ictal semiology and electroclinical findings to support the diagnosis of LGS until age 14 and 32 years, respectively. One patient had absence seizures beginning at age 9 years and was seizure free on valproic acid until age 14 years. The other patient had generalized epilepsy beginning at age 5 years, which was well controlled on medication until age 32 years. The mean age at first appointment at Mayo Clinic was 27.8 years (range, 15-47), and patients were followed up for 36.2 months (range, 0-116 months). Two patients had a family history of epilepsy, and 1 patient had a history of "febrile-related" seizures. All patients had tonic, atonic, and generalized tonic-clonic seizures. Myoclonic seizures were reported in 3 patients and atypical absence in 7 patients. Five patients had normal intellectual function before LGS onset. Two patients had a history of status epilepticus, both after the onset of LGS.
EEG
All patients had inpatient video-EEG recordings in the epilepsy monitoring unit. Seizures were recorded in all patients. Seizure types included atonic (n = 7), tonic (n = 6), atypical absence (n = 5), generalized tonic-clonic (n = 1), myoclonic (n = 1), and focal (n = 1). The patient with focal seizures also had generalized atonic seizures. In all patients, the interictal and ictal EEG patterns supported the diagnosis of LGS (figures 1 and 2). Generalized paroxysmal fast activity was recorded in all patients, and slow spike and wave was identified in 2 (18%). Interictal generalized atypical spike or polyspike and wave discharges were recorded in all patients. In addition, interictal focal/multifocal epileptogenic discharges were recorded in 8.
Neuroimaging
All patients had a MRI head study (table) . The brain morphology was normal in 7 patients. Two patients had malformations of cortical development. One patient had a congenital brain anomaly (colpocephaly).
Cerebrospinal fluid
Five patients underwent cerebrospinal fluid (CSF) analysis. The mean CSF protein level was mildly elevated at 54 mg/dL (range, 43-68 mg/dL; normal, 0-35 mg/dL). The remainder of the CSF findings were unremarkable-mean nucleated cell count: 1.6 (range, 1-4; normal value, 0-5); mean oligoclonal bands (n = 4): 0 (normal value, <4); and mean immunoglobulin G index: 0.54 (range, 0.48-0.6; normal value, <0.85).
Etiology
An underlying etiology was suggested by history in 3 of the 10 patients. Two patients had a history of acute lymphoblastic leukemia (ALL) as young children. They both received Lennox-Gastaut syndrome is a potentially catastrophic epileptic syndrome accounting for 1%-10% of childhood epilepsies. intrathecal methotrexate as part of their treatment regimen, and one also received cranial radiation. One patient had a complex neuropsychiatric history with an outside diagnosis of pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection and underwent previous treatment with IV immunoglobulin. No definitive cause could be confirmed in 7 patients despite an extensive evaluation. Genetic workup was limited but uninformative. Two patients had unrevealing testing for EPM2A and EPM2B genes for progressive myoclonic epilepsy. One patient had normal SCN1A and SCN1B gene testing. Chromosomal microarray was normal in 2 patients. One patient had a comprehensive epilepsy gene panel revealing variants of uncertain significance in KMT2D, SCN3A, FARS2, CLCNKA, SLC46A1, and ATP13A2 genes but no known pathologic mutation. Autoantibody determinations for autoimmune epilepsy were obtained in 5 patients; serum and CSF were checked in 4 patients and CSF alone in one. One patient did have potassium channel and acetylcholine receptor ganglionic neuronal antibodies in the serum, which on repeat testing 4 months later were not present. Testing for LGI1 and CASPR2 was not performed, likely due to the timing of this testing.
Treatment
The mean number of ASDs tried was 11.7, with a median of 12 (range, 7-16). Medications and treatment modalities used in the 10 patients included clobazam (n = 9), felbamate (n = 8), divalproex sodium (n = 10), rufinamide (n = 10), medical marijuana (n = 2), dietary therapy (ketogenic and/ or modified Atkins diet) (n = 5), vagus nerve stimulation (VNS) (n = 7), and deep brain stimulation targeting bilateral centromedian and anterior nucleus of the thalamus (n = 1). None of the patients underwent corpus callosotomy.
Outcome
At final follow-up, 9 patients required a caregiver and did not live independently because of intractable epilepsy, including 4 who had normal intellectual function at onset. No patients were able to drive. Psychiatric comorbidities were identified in 4 during the follow-up period, including behavioral dyscontrol, obsessive compulsive behaviors, psychosis, and depression with hallucinations. One patient died of probable sudden unexpected death in epilepsy (SUDEP).
Discussion
LGS is a rare and disabling disorder that usually presents in early childhood with a peak age at onset between 3 and 5 years and is an epileptic encephalopathy with progressive In the current patient series, the diagnosis of LGS occurred at a mean age of 16.5 years, much older than the typical presentation of this catastrophic epileptic syndrome.
impairment in cognitive and behavioral abilities. 1, 2 The epileptic syndrome may be more difficult to diagnose in adults because of varied and atypical presentations. 7 The clinical course of late-onset LGS has not been well described previously. Diagnostic and clinical features may evolve in patients over time and may not all be present at seizure onset. 1 In the current patient series, the diagnosis of LGS occurred at a mean age of 16.5 years, much older than the typical presentation of this catastrophic epileptic syndrome. Most patients were female in contrast to the male predominance of 5 to 1, which has been reported in LGS. 4 All patients in the present study had drug-resistant generalized epilepsy with considerable progressive comorbidities. The treatment modalities commonly used in the management of patients with LGS, including ASDs and VNS, had limited efficacy in our patients. Seven of the patients required the placement of a VNS. Only 1 patient reported efficacy with VNS and this was only in regard to atypical absence seizures; drop attacks continued. The overall outcome was socially and physically disabling similar to what is reported in younger patients. Only 1 patient remained independent and able to maintain a job. This patient had normal intellectual function at LGS onset and seizures beginning at age 5, which were well controlled on medication until age 32 years. He had tried 12 ASDs and was on 4 medications at final follow-up continuing to experience frequent generalized tonic seizures. All other patients were essentially dependent, including the other 4 patients who had a normal intellectual function at onset. The dependency in the latter patients was due to the risks and falls posed by their disabling seizures. One patient died of suspected SUDEP. This patient had normal intellectual function at seizure onset. She had used 12 ASDs, ketogenic diet, and VNS. Despite these interventions, she continued to have difficulty to control seizures and progressive cognitive difficulties.
The etiology of LGS was cryptogenic in most of the patients in the present series. Two patients had a history of ALL as young children. They both received intrathecal methotrexate as part of their treatment regimen and one also received cranial radiation. Seizures are seen in 8%-13% of patients with ALL, usually during acute treatment of the disease. 8 Intractable epilepsy resulting from treatment of ALL is less frequently described. A previous case series described 5 patients treated for ALL who all went on to develop epilepsy requiring trials of multiple AEDs. 8 In addition, patients have been previously described who developed LGS during childhood after treatment. 9 Late-onset LGS has been described in patients with genetic mutations, including 15q duplication and trisomy 21. 5, 6, 10 In addition, late onset of atonic seizures have been described in 17 previously reported patients who had generalized epilepsy onset at a younger age. 11 Park et al. 3 described 3 patients who were considered to have late-onset LGS with normal intellectual ability. 3 In these patients, reduced fractional anisotropy in the white matter of the brainstem was present, suggesting that brainstem dysfunction may contribute to the pathophysiology of late-onset LGS. 3 The authors speculated that late-onset LGS may have less damaging effects on cognition, given the brain has already gone through critical developmental stages. 3 Despite this in our reported cases, progressive cognitive impairment was frequent.
The clinical and EEG features supported the diagnosis of lateonset LGS in all patients. Generalized paroxysmal fast activity was invariably present in this series. Slow spike wave was less frequently identified. These findings are typical of normalonset LGS. Generalized paroxysmal fast activity is a feature that is likely to persist into adulthood in LGS. 4 In a retrospective study of 27 patients with LGS followed into Figure 2 Ictal EEG Generalized high-amplitude sharply contoured slow wave (first arrow), followed by diffuse electrodecremental response (second arrow) in a 35-year-old patient with late-onset Lennox-Gastaut syndrome (patient 1) during an atonic seizure.
adulthood by Ferlazzo et al., 12 44% had normalization of the background activity, with 74% having a reduction in epileptic discharges during wakefulness. However, diffuse fast rhythms in sleep persisted in all patients. 12 Generalized paroxysmal fast activity is associated with nocturnal tonic seizures. 13 CSF analysis was performed in 5 patients. All cases demonstrated a mildly elevated CSF protein level without pleocytosis, suggesting a mild degree of inflammation. A previous study looking at CSF after epileptic seizures demonstrated an elevated CSF protein level in 60.9%.
14 An elevated protein level was more common in patients with generalized seizures. 14 It is hypothesized that a transient disturbance of the blood-brain barrier during seizure activity is what leads to the elevation of the protein level in the CSF. We do not have data in our study to demonstrate the time between the last seizure and CSF analysis. However, given the high seizure burden, it is plausible that ongoing seizure activity could have increased the CSF protein in our cohort. Nonetheless, the elevation of the CSF protein level raises the question whether an underlying inflammatory pathogenic mechanism is present in these patients.
There are important limitations of this study including the size of the patient cohort and the observational and retrospective study design. Two of our patients did have seizure onset before age 10 years but were well controlled on medications. The electroclinical correlation changed at an older age, justifying the diagnosis of late-onset LGS. This case series demonstrates the severity of this epileptic syndrome, even with onset at an older age, and the devastating psychosocial effects. Drug-resistant epilepsy was invariably present, and progressive cognitive impairment was a common feature.
TAKE-HOME POINTS
Lennox-Gastaut syndrome usually presents between 3 and 5 years of age but rarely can have onset later in life.
Late-onset Lennox-Gastaut syndrome is a disabling epileptic syndrome, which can be associated with progressive cognitive impairment.
Elevated CSF protein levels were found in all patients tested in our cohort, which could be related to seizure activity but raises concern for an inflammatory component.
